These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33154241)

  • 41. Comparative evaluation of plazomicin MICs obtained using agar dilution versus broth microdilution methods and impact of inoculum size against ESBL-producing Escherichia coli, carbapenemase-producing Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus clinical isolates.
    Emiliov T; Rodríguez-Avial I; López-Diaz MDC; Culebras E
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114867. PubMed ID: 31402069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
    Martins AF; Bail L; Ito CAS; da Silva Nogueira K; Dalmolin TV; Martins AS; Rocha JLL; Serio AW; Tuon FF
    Diagn Microbiol Infect Dis; 2018 Mar; 90(3):228-232. PubMed ID: 29223516
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.
    Walkty A; Adam H; Baxter M; Denisuik A; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2014 May; 58(5):2554-63. PubMed ID: 24550325
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region.
    Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR
    J Antimicrob Chemother; 2021 Jul; 76(8):2061-2070. PubMed ID: 34097032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dissemination of clonal complex 2 Acinetobacter baumannii strains co-producing carbapenemases and 16S rRNA methylase ArmA in Vietnam.
    Tada T; Miyoshi-Akiyama T; Shimada K; Nga TT; Thu le TA; Son NT; Ohmagari N; Kirikae T
    BMC Infect Dis; 2015 Oct; 15():433. PubMed ID: 26471294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Co-occurrence of carbapenem and aminoglycoside resistance genes among multidrug-resistant clinical isolates of Acinetobacter baumannii from Cracow, Poland.
    Nowak P; Paluchowska PM; Budak A
    Med Sci Monit Basic Res; 2014 Jan; 20():9-14. PubMed ID: 24463791
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.
    Mezzatesta ML; Caio C; Gona F; Cormaci R; Salerno I; Zingali T; Denaro C; Gennaro M; Quattrone C; Stefani S
    Int J Antimicrob Agents; 2014 Aug; 44(2):112-6. PubMed ID: 25059444
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determination of synergy between sulbactam, meropenem and colistin in carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii isolates and correlation with the molecular mechanism of resistance.
    Laishram S; Anandan S; Devi BY; Elakkiya M; Priyanka B; Bhuvaneshwari T; Peter JV; Subramani K; Balaji V
    J Chemother; 2016 Aug; 28(4):297-303. PubMed ID: 27461479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A culture medium for screening 16S rRNA methylase-producing pan-aminoglycoside resistant Gram-negative bacteria.
    Nordmann P; Mazé A; Culebras E; Dobias J; Jayol A; Poirel L
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):118-122. PubMed ID: 29496380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antimicrobial resistance determinants in imipenem-nonsusceptible Acinetobacter calcoaceticus-baumannii complex isolated in Daejeon, Korea.
    Sung JY; Kwon KC; Cho HH; Koo SH
    Korean J Lab Med; 2011 Oct; 31(4):265-70. PubMed ID: 22016680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multicentre investigation of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Bulgarian hospitals - Interregional spread of ST11 NDM-1-producing K. pneumoniae.
    Markovska R; Stoeva T; Boyanova L; Stankova P; Schneider I; Keuleyan E; Mihova K; Murdjeva M; Sredkova M; Lesseva M; Nedelcheva G; Petrova A; Ivanova D; Lazarova G; Kaneva R; Mitov I
    Infect Genet Evol; 2019 Apr; 69():61-67. PubMed ID: 30654179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of in vitro activities of plazomicin and other aminoglycosides against clinical isolates of Klebsiella pneumoniae and Escherichia coli.
    İnce G; Mirza HC; Üsküdar Güçlü A; Gümüş H; Erol Ç; Başustaoğlu A
    J Antimicrob Chemother; 2021 Nov; 76(12):3192-3196. PubMed ID: 34499728
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing.
    Arca-Suárez J; Rodiño-Janeiro BK; Pérez A; Guijarro-Sánchez P; Vázquez-Ucha JC; Cruz F; Gómez-Garrido J; Alioto TS; Álvarez-Tejado M; Gut M; Gut I; Oviaño M; Beceiro A; Bou G;
    Int J Antimicrob Agents; 2022 Jan; 59(1):106456. PubMed ID: 34688835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of 16S rRNA methylase, modifying enzyme, and extended-spectrum beta-lactamase genes among Acinetobacter baumannii isolates.
    Liu Z; Ling B; Zhou L
    J Chemother; 2015 Aug; 27(4):207-12. PubMed ID: 24766153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distribution and molecular characterization of carbapenemase-producing gram-negative bacteria in Henan, China.
    Li C; Chen R; Qiao J; Ge H; Fang L; Liu R; Liu S; Wang Q; Guo X; Gou J
    Sci Rep; 2024 Jun; 14(1):14418. PubMed ID: 38909136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Attwood M; Bowker KE; Kim A; Krause KM; MacGowan AP
    Int J Antimicrob Agents; 2019 Nov; 54(5):626-632. PubMed ID: 31299297
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-level aminoglycoside resistance in
    Upadhyay S; Khyriem AB; Bhattacharya P; Bhattacharjee A; Joshi SR
    Indian J Med Microbiol; 2018; 36(1):43-48. PubMed ID: 29735825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections.
    Bilinskaya A; Linder KE; Kuti JL
    Expert Rev Anti Infect Ther; 2020 Aug; 18(8):705-720. PubMed ID: 32319833
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aminoglycoside Resistance: Updates with a Focus on Acquired 16S Ribosomal RNA Methyltransferases.
    Wachino JI; Doi Y; Arakawa Y
    Infect Dis Clin North Am; 2020 Dec; 34(4):887-902. PubMed ID: 33011054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.